tirzepatide hepatic impairment child-pugh Child–Turcotte–Pugh classification a to assess severity of chronic Tirzepatide Half-Life Plotter: Understanding Drug

Some Medicaid beneficiaries may have prescription drug coverage for Mounjaro, while others may be subject to prior authorization requirements, diagnosis restrictions, or additional clinical criteria

Both are used in patients with polycystic ovarian syndrome and obesity

Known as a dual agonist, Tirzepatide has shown significant weight loss results for many individuals

Patients for whom the higher magnitude of average weight loss is needed to support meaningful improvement in conditions such as sleep apnoea, severe insulin resistance, or non-alcoholic fatty liver disease

They may also be considered in cases of insulin resistance, prediabetes, or other weight-related health concerns